{"id":690268,"date":"2022-09-29T08:38:05","date_gmt":"2022-09-29T12:38:05","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\/"},"modified":"2022-09-29T08:38:05","modified_gmt":"2022-09-29T12:38:05","slug":"palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\/","title":{"rendered":"Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">\n        <strong>Carlsbad,\u00a0CA, Sept.  29, 2022  (GLOBE NEWSWIRE) &#8212; <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7pEnLcb5zGVLwEEA1Hfk0sYkuxnuOHz43knrMIU-nV9LlSANRShDAd15y8KaRKZdnHNLzzev0wI-bB64D3NCvQ==\" rel=\"nofollow noopener\" target=\"_blank\">Palisade Bio<\/a><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=62jxhMd1KY0TYgovdVlQasp7RoFN6KAF9DcGxYZ1F1PlzpvuAwJpzX4aYJ4I5009PXw1wEHwb3GL0WZSrHBLdA==\" rel=\"nofollow noopener\" target=\"_blank\">, Inc.<\/a><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4xbEeicyuiR24buxLK31_2i2RJBwg9lwDbax2iwEx2pcOKzAQtlTVQeOCCcnlsddD8APQCHJtjUS9PECh_dsoQ==\" rel=\"nofollow noopener\" target=\"_blank\">\u00a0<\/a>(Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced its abstract was accepted for presentation at the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AJDYv9jcb31JRPx_LyoPeST3JjPWd6aQ1mr28lHf_rV8R_Yb6KRDGTC5U_z7YM0G8ZNljlfs64q_NKr7LrAG3hJpdlwtjhXdAhi6jEex0xYPWiygk2ZedPk-XvgoUvI-Jn71Zvzz0-G-ScWxJ_GdeCIFrZbojJ7T2whIzN94XwM-xy8pe9hzvvqQEB-ZsB6LlgxlDgbstE__QJoCWFJFXQ_dIOnIefUCWaXbtr0E-pA=\" rel=\"nofollow noopener\" target=\"_blank\">American College of Surgeons (ACS) Clinical Congress 2022<\/a> being held October 16-20, 2022, in San Diego, CA.<\/p>\n<p align=\"justify\">Details of the abstract presentation are as follows:<\/p>\n<p align=\"justify\">\n        <strong>Session<\/strong><br \/>\n        <strong>: <\/strong>Colon and Rectal Surgery I<br \/><strong>Title<\/strong><strong>: <\/strong><em>LB1148 An Enteral Protease Inhibitor Significantly Accelerated the Return of Bowel Function after Bowel Resection<\/em><br \/><strong>Presenter: <\/strong>Michael Dawson, M.D., Chief Medical Officer of Palisade Bio<br \/><strong>Date &amp; Time:<\/strong> Monday, October 17, 2022, 4:15 \u2013 5:45 PM ET<\/p>\n<p align=\"justify\">The abstract is now available and can be accessed in the Congress Program Planner, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=58nTrik5q4T2saQhBYzH2vnsR1taJ63QHjT-tQ1tkrzeMQjaIjeiVa1khzS62lPE0--_RRwFpu1wL-kybXOog6xXW-ngBw0RZYKSqDIOUw-r9c63IzEeIcX5t83IzW8e\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>. The oral presentation will include new GI functional data sub-cuts from the highly statistically significant Phase 2 clinical study (NCT05056935) demonstrating LB1148 significantly accelerated the return of post-operative GI function in patients undergoing elective bowel resection. The data sub-cuts are based on laparoscopy and laparotomy with surgical characteristics including, right hemicolectomy, left hemicolectomy, sigmoid and low anterior resection (LAR) surgery. These patient groups are being included for presentation as they represent key patient populations being enrolled in the ongoing Phase 3 clinical study of LB1148 to accelerate the return of post-operative GI function in patients undergoing elective bowel resection. <\/p>\n<p><strong>About Palisade Bio\u00a0<\/strong><\/p>\n<p align=\"justify\">Palisade Bio is a late-stage biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The Company utilizes over three decades of research and established science that links the role of intestinal barrier biology and human disease to develop novel therapeutics that target and improve the integrity of the intestinal barrier.<\/p>\n<p align=\"justify\">The Company\u2019s lead program, LB1148, is a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, potentially reducing intestinal damage. In multiple clinical studies, LB1148 has demonstrated positive results in accelerating the time to return of postoperative bowel function, and the Company recently presented analysis that LB1148 reduced the incidence and severity of post-surgical abdominal adhesions. LB1148 is currently being evaluated in a pivotal Phase 3 clinical study for accelerating the return of postoperative bowel function and in a Phase 2 study for the prevention of post-surgical abdominal adhesions.<\/p>\n<p align=\"justify\">The Company believes that addressing the disruption of the intestinal barrier has the potential to fundamentally change the way diseases are treated and to establish new standards of patient care. For more information, please go to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZrhRef07yhYx9lRpA0zBCbDhsaYNIZU9_NTYyC6XjyRJGOS1s7G8QHcntL0nLMbq90Pn7tscWDEK80IP48NoUbHMCxo88DP2gsKyrPa6fe5RaNJMLdkhlwiPEJb0bko2lt_EZptkvNqS0QvKYEC1UTlkb_7m479F_V2HsXEu9HDHQE0dk2muEF9qXVCbVbb9ItP7ymbw3Sqd6u-RDY3rV-N4WTHCgqbP2bowZyXvy1OlMSt4R8-8Om5WmWr15l_h\" rel=\"nofollow noopener\" target=\"_blank\">www.palisadebio.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward Looking Statements<\/strong><br \/>\n        <br \/>This communication contains \u201cforward-looking\u201d statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Palisade\u2019s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential to fundamentally change the way diseases are treated, the completion of enrollment for the Phase 3 study, the potential for the statistically significant Phase 3 data to allow for NDA approval, and the potential for LB1148 to establish the standard of care, if approved. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Palisade\u2019s current expectations. Forward-looking statements involve risks and uncertainties. Palisade\u2019s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the company\u2019s ability to advance its clinical programs, the uncertain and time-consuming regulatory approval process; the company\u2019s ability to achieve additional financing to fund clinical development and the company\u2019s ability to comply with the continued listing requirements for Nasdaq. Additional risks and uncertainties can be found in Palisade Bio\u2019s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022.\u00a0Palisade expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Palisade\u2019s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based<em>.<\/em><\/p>\n<p>\n        <strong>Investor Relations Contact<\/strong><br \/>\n        <br \/>JTC Team, LLC<br \/>Jenene Thomas <br \/>833-475-8247<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QRHqjEsrenCDgr9Jw5ryl4d76RAK76Qe8ny9U9OpGLyuYcpP06oYkMnz81jS1GGKYIfHBjmlCJeYxsLa5I8JFg==\" rel=\"nofollow noopener\" target=\"_blank\">PALI@jtcir.com<\/a><\/p>\n<p>Source: Palisade Bio<\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NTY2NSM1MTc4MzYwIzUwMDEwOTEyMQ==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/N2Y5MjYyNjEtMTg1OS00MGFkLWE0MTItN2ZkMzA1Y2ZhNjRiLTUwMDEwOTEyMQ==\/tiny\/Palisade-Bio-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Carlsbad,\u00a0CA, Sept. 29, 2022 (GLOBE NEWSWIRE) &#8212; Palisade Bio , Inc. \u00a0(Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced its abstract was accepted for presentation at the American College of Surgeons (ACS) Clinical Congress 2022 being held October 16-20, 2022, in San Diego, CA. Details of the abstract presentation are as follows: Session : Colon and Rectal Surgery ITitle: LB1148 An Enteral Protease Inhibitor Significantly Accelerated the Return of Bowel Function after Bowel ResectionPresenter: Michael Dawson, M.D., Chief Medical Officer of Palisade BioDate &amp; Time: Monday, October 17, 2022, 4:15 \u2013 5:45 PM ET The abstract is now available and can be accessed in the Congress Program Planner, here. The &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-690268","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Carlsbad,\u00a0CA, Sept. 29, 2022 (GLOBE NEWSWIRE) &#8212; Palisade Bio , Inc. \u00a0(Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced its abstract was accepted for presentation at the American College of Surgeons (ACS) Clinical Congress 2022 being held October 16-20, 2022, in San Diego, CA. Details of the abstract presentation are as follows: Session : Colon and Rectal Surgery ITitle: LB1148 An Enteral Protease Inhibitor Significantly Accelerated the Return of Bowel Function after Bowel ResectionPresenter: Michael Dawson, M.D., Chief Medical Officer of Palisade BioDate &amp; Time: Monday, October 17, 2022, 4:15 \u2013 5:45 PM ET The abstract is now available and can be accessed in the Congress Program Planner, here. The &hellip; Continue reading &quot;Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-29T12:38:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NTY2NSM1MTc4MzYwIzUwMDEwOTEyMQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022\",\"datePublished\":\"2022-09-29T12:38:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\\\/\"},\"wordCount\":690,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NTY2NSM1MTc4MzYwIzUwMDEwOTEyMQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\\\/\",\"name\":\"Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NTY2NSM1MTc4MzYwIzUwMDEwOTEyMQ==\",\"datePublished\":\"2022-09-29T12:38:05+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NTY2NSM1MTc4MzYwIzUwMDEwOTEyMQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY1NTY2NSM1MTc4MzYwIzUwMDEwOTEyMQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\/","og_locale":"en_US","og_type":"article","og_title":"Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022 - Market Newsdesk","og_description":"Carlsbad,\u00a0CA, Sept. 29, 2022 (GLOBE NEWSWIRE) &#8212; Palisade Bio , Inc. \u00a0(Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced its abstract was accepted for presentation at the American College of Surgeons (ACS) Clinical Congress 2022 being held October 16-20, 2022, in San Diego, CA. Details of the abstract presentation are as follows: Session : Colon and Rectal Surgery ITitle: LB1148 An Enteral Protease Inhibitor Significantly Accelerated the Return of Bowel Function after Bowel ResectionPresenter: Michael Dawson, M.D., Chief Medical Officer of Palisade BioDate &amp; Time: Monday, October 17, 2022, 4:15 \u2013 5:45 PM ET The abstract is now available and can be accessed in the Congress Program Planner, here. The &hellip; Continue reading \"Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\/","og_site_name":"Market Newsdesk","article_published_time":"2022-09-29T12:38:05+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NTY2NSM1MTc4MzYwIzUwMDEwOTEyMQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022","datePublished":"2022-09-29T12:38:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\/"},"wordCount":690,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NTY2NSM1MTc4MzYwIzUwMDEwOTEyMQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\/","name":"Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NTY2NSM1MTc4MzYwIzUwMDEwOTEyMQ==","datePublished":"2022-09-29T12:38:05+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NTY2NSM1MTc4MzYwIzUwMDEwOTEyMQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY1NTY2NSM1MTc4MzYwIzUwMDEwOTEyMQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/palisade-bio-announces-oral-presentation-of-phase-2-data-at-the-american-college-of-surgeons-acs-clinical-congress-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons (ACS) Clinical Congress 2022"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/690268","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=690268"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/690268\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=690268"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=690268"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=690268"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}